Bluejay Diagnostics Shares Scheduled to Reverse Split on Tuesday, November 3rd (NASDAQ:BJDX)

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) shares are scheduled to reverse split before the market opens on Tuesday, November 3rd. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, November 2nd.

Bluejay Diagnostics Price Performance

BJDX stock traded down $0.03 during mid-day trading on Monday, reaching $0.53. The company had a trading volume of 181,513 shares, compared to its average volume of 2,220,212. The stock has a 50 day simple moving average of $0.82 and a two-hundred day simple moving average of $1.85. The company has a market capitalization of $2.37 million, a price-to-earnings ratio of -0.07 and a beta of 0.93. Bluejay Diagnostics has a 52 week low of $0.46 and a 52 week high of $7.92.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($1.12) earnings per share for the quarter, topping the consensus estimate of ($3,520.00) by $3,518.88.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on BJDX shares. Wall Street Zen cut shares of Bluejay Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday, September 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Monday, September 21st. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Bluejay Diagnostics has an average rating of “Sell”.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc is a medical technology company focused on developing rapid, point-of-care diagnostic testing solutions. The company’s technology is designed to provide healthcare professionals with timely information from blood samples, supporting clinical decision-making in settings where conventional laboratory testing may take longer.

Its primary product is the Symphony system, a diagnostic platform consisting of an analyzer and disposable test cartridges. The platform is intended to measure biomarkers in whole blood and is being developed for applications including the assessment and management of serious medical conditions such as sepsis and other critical-care situations.

Bluejay Diagnostics is headquartered in Acton, Massachusetts, and serves the healthcare market through the development of diagnostic products for hospitals, clinics and other point-of-care environments.